Document Detail

The effects of gynaecological surgery on coagulation activation, fibrinolysis and fibrinolytic inhibitor in patients with and without ketorolac infusion.
MedLine Citation:
PMID:  7502276     Owner:  NLM     Status:  MEDLINE    
The effects of gynaecological surgery on the fibrinolytic and inhibitor mechanisms were followed up for 24 h post-operatively in patients receiving a single dose of ketorolac infusion (n = 18) as compared with those not receiving ketorolac infusion (n = 11). A pre-operative state of lower mean t-PA activity and higher PAI-1 levels with increased platelet activation than that reported in normal subjects were observed in both groups of patients. Increased t-PA activity upon anaesthetic induction together with a decreased level at 24 h post-operation was seen in both groups. However, fibrinolytic 'shut-down' was not evident as significant increase in D-dimer levels was observed post-operatively, suggesting an enhanced lytic state concurrent with an enhanced activation of coagulation and diminished platelet activation although beta-TG remained above the normal level; plasmin from this enhanced lytic state affects platelet adhesion and cleaves platelet glycoprotein Ib thus inhibit release reaction. Ketorolac infusion elicited a significant response in PAI-1 activity within 24 h post-operation and this was not seen in the non-ketorolac group in spite of the rising trend by 24 h post-operation which did not achieve statistical significance. There were no statistical significant differences in blood loss and duration of surgery between the two groups of patients. Overall, both groups of patients showed similar haemostatic changes post-operatively for 24 h, a longer duration of post-operative study would have revealed any subtle changes in the molecular markers of thrombosis which was not the objective of this study.
S C Koh; H L Pua; D H Tay; S S Ratnam
Related Documents :
19707386 - Analysis and variability of tgfbeta measurements in cancer patients with skeletal metas...
23710476 - Use of platelet-rich plasma to enhance tendon function and cellularity.
12398166 - Radiographic evaluation of the effect of endotoxin (lps) plus calcium hydroxide on apic...
20149696 - A combination graft of low-molecular-weight silk fibroin with choukroun platelet-rich f...
23812196 - Changes in the mean platelet volume levels after bloodstream infection have prognostic ...
9271786 - Oxidative stress and the mobilisation of arachidonic acid in stimulated human platelets...
Publication Detail:
Type:  Clinical Trial; Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Thrombosis research     Volume:  79     ISSN:  0049-3848     ISO Abbreviation:  Thromb. Res.     Publication Date:  1995 Sep 
Date Detail:
Created Date:  1996-01-18     Completed Date:  1996-01-18     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0326377     Medline TA:  Thromb Res     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  501-14     Citation Subset:  IM    
Department of Obstetrics and Gynaecology, National University of Singapore, National University Hospital.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anti-Inflammatory Agents, Non-Steroidal / therapeutic use*
Antifibrinolytic Agents / therapeutic use*
Antithrombin III / metabolism
Blood Coagulation / drug effects*
Cyclooxygenase Inhibitors / therapeutic use*
Fibrin Fibrinogen Degradation Products / metabolism
Fibrinolysis / drug effects*
Genital Diseases, Female / blood*,  surgery
Middle Aged
Peptide Hydrolases / metabolism
Plasminogen Activator Inhibitor 1 / therapeutic use
Plasminogen Activators / therapeutic use
Tolmetin / analogs & derivatives,  therapeutic use
beta-Thromboglobulin / metabolism
Reg. No./Substance:
0/Anti-Inflammatory Agents, Non-Steroidal; 0/Antifibrinolytic Agents; 0/Cyclooxygenase Inhibitors; 0/Fibrin Fibrinogen Degradation Products; 0/Plasminogen Activator Inhibitor 1; 0/antithrombin III-protease complex; 0/beta-Thromboglobulin; 0/fibrin fragment D; 26171-23-3/Tolmetin; 66635-83-4/Ketorolac; 9000-94-6/Antithrombin III; EC 3.4.-/Peptide Hydrolases; EC 3.4.21.-/Plasminogen Activators

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Design and synthesis of thrombin substrates with modified kinetic parameters.
Next Document:  "Cardioplegia on the contractile apparatus level": evaluation of a new concept for myocardial preser...